DE3235093C2 - - Google Patents

Info

Publication number
DE3235093C2
DE3235093C2 DE3235093A DE3235093A DE3235093C2 DE 3235093 C2 DE3235093 C2 DE 3235093C2 DE 3235093 A DE3235093 A DE 3235093A DE 3235093 A DE3235093 A DE 3235093A DE 3235093 C2 DE3235093 C2 DE 3235093C2
Authority
DE
Germany
Prior art keywords
dops
threo
dopa
parkinson
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE3235093A
Other languages
German (de)
English (en)
Other versions
DE3235093A1 (de
Inventor
Hirotaro Narabayashi
Tomoyoshi Tokio/Tokyo Jp Kondo
Akira Suita Osaka Jp Hayashi
Tomokazu Kobe Hyogo Jp Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Chemical Co Ltd
Original Assignee
Sumitomo Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Chemical Co Ltd filed Critical Sumitomo Chemical Co Ltd
Publication of DE3235093A1 publication Critical patent/DE3235093A1/de
Application granted granted Critical
Publication of DE3235093C2 publication Critical patent/DE3235093C2/de
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE19823235093 1981-09-22 1982-09-22 Antiparkinsonmittel Granted DE3235093A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56150082A JPS5852219A (ja) 1981-09-22 1981-09-22 パ−キンソン病治療剤

Publications (2)

Publication Number Publication Date
DE3235093A1 DE3235093A1 (de) 1983-04-07
DE3235093C2 true DE3235093C2 (OSRAM) 1988-12-29

Family

ID=15489114

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19823235093 Granted DE3235093A1 (de) 1981-09-22 1982-09-22 Antiparkinsonmittel

Country Status (13)

Country Link
US (1) US4497826A (OSRAM)
JP (1) JPS5852219A (OSRAM)
AU (2) AU556542B2 (OSRAM)
BE (1) BE894451A (OSRAM)
CA (1) CA1184501A (OSRAM)
CH (1) CH650926A5 (OSRAM)
DE (1) DE3235093A1 (OSRAM)
FR (1) FR2513117B1 (OSRAM)
GB (1) GB2106388B (OSRAM)
IT (1) IT1212668B (OSRAM)
NL (1) NL189648C (OSRAM)
NZ (1) NZ201864A (OSRAM)
SE (1) SE462781B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6067420A (ja) * 1983-09-22 1985-04-17 Sumitomo Chem Co Ltd 精神運動興奮抑制剤
NZ209514A (en) * 1983-09-22 1988-03-30 Sumitomo Chemical Co Pharmaceutical compositions containing erythro-3,4-dihydroxyphenylserine and a decarboxylase inhibitor
AU575849B2 (en) * 1983-09-22 1988-08-11 Sumitomo Chemical Company, Limited Pharmaceutical composition and method for treatment of psychomotor excitement
JPS60132935A (ja) * 1983-12-20 1985-07-16 Sumitomo Chem Co Ltd フエニルセリン誘導体及びその製造方法
JPS6185318A (ja) * 1984-10-04 1986-04-30 Sumitomo Seiyaku Kk 利尿薬
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
ZA889189B (en) * 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
US4863962A (en) * 1988-03-02 1989-09-05 Fidia-Georgetown Institute For The Neurosciences D-DOPA, pharmaceutically acceptable salts thereof, and methods of treating Parkinson's disease
PT99864B (pt) * 1990-12-21 1999-06-30 Schering Ag Processo para a preparacao de novas composicoes farmaceuticas contendo antagonistas de receptor de quisqualato
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
JP3559572B2 (ja) 1993-01-29 2004-09-02 住友製薬株式会社 急性痛および慢性痛用鎮痛剤
JP3764179B2 (ja) * 1994-07-05 2006-04-05 克寛 西野 運動・意識または言語障害の機能改善剤
US5668114A (en) * 1996-05-08 1997-09-16 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating hypertension
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US7786126B2 (en) * 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
EP2363124B1 (en) * 2006-06-28 2016-02-17 Lundbeck NA Ltd Pharmaceutical compositions comprising droxidopa
AU2008226541B2 (en) * 2007-03-09 2013-05-09 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
EP2514417A3 (en) * 2007-05-07 2013-01-30 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
EP2450343A4 (en) 2009-07-01 2013-01-09 Dainippon Sumitomo Pharma Co PROCESS FOR PREPARING THREO-3- (3,4-DIHYDROXYPHENYL) L-SERIN
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE34275B1 (en) * 1969-06-18 1975-03-19 Merck & Co Inc Alpha-hydrazino acids
US3658968A (en) * 1970-06-11 1972-04-25 Merck & Co Inc Composition and method of treatment
DE2305209A1 (de) * 1972-02-14 1973-08-23 Hoffmann La Roche Pharmazeutisches praeparat
AU6889274A (en) * 1973-05-17 1975-11-20 Astra Laekemedel Ab Treatment of neurological disorders
US3920728A (en) * 1973-08-22 1975-11-18 Hoffmann La Roche Separation and resolution of isomeric forms of 3-(3,4-dihydroxy-phenyl)-serine
CH580059A5 (OSRAM) * 1973-08-22 1976-09-30 Hoffmann La Roche
JPS52125630A (en) * 1976-04-14 1977-10-21 Kyowa Hakko Kogyo Co Ltd Antiperkinson drugs containing l-threo-3,4-dihydroxyphenylserine
JPS56104815A (en) * 1980-01-23 1981-08-20 Sumitomo Chem Co Ltd Remedy for peripheral orthostatic hypotension

Also Published As

Publication number Publication date
CA1184501A (en) 1985-03-26
NL189648C (nl) 1993-06-16
AU556542B2 (en) 1986-11-06
NL8203594A (nl) 1983-04-18
AU8857882A (en) 1983-03-31
SE8205404D0 (sv) 1982-09-21
US4497826A (en) 1985-02-05
AU575267B2 (en) 1988-07-21
JPS5852219A (ja) 1983-03-28
FR2513117A1 (fr) 1983-03-25
CH650926A5 (de) 1985-08-30
FR2513117B1 (fr) 1986-01-24
GB2106388A (en) 1983-04-13
SE8205404L (sv) 1983-03-23
BE894451A (fr) 1983-03-21
AU6750187A (en) 1987-04-16
NL189648B (nl) 1993-01-18
IT8268118A0 (it) 1982-09-21
NZ201864A (en) 1985-12-13
IT1212668B (it) 1989-11-30
JPH0216284B2 (OSRAM) 1990-04-16
GB2106388B (en) 1986-03-26
SE462781B (sv) 1990-09-03
DE3235093A1 (de) 1983-04-07

Similar Documents

Publication Publication Date Title
DE3235093A1 (de) Antiparkinsonmittel
DE69822665T2 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
DE69533940T2 (de) Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren
DE60120104T2 (de) Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DE69715862T2 (de) Verwendung eines k-252a derivats zur behandlung von periphärer oder zentraler nervenerkrankungen und übermässiger cytokinbildung
EP1572181A2 (de) Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor und deren verwendung zur behandlung von blasenfunktionsstoerungen
DE3137125C2 (OSRAM)
DE3686108T2 (de) Verwendung von p-chlorophenoxyazetat von n,n-dimethylbiguanid zur behandlung von neuropathien und nervendegeneration.
DE4343592C2 (de) Verwendung von R-(+)-alpha-Liponsäure und dessen Metaboliten in Form der freien Säure oder als Salze oder Ester oder Amide zur Behandlung von Glukosestoffwechselstörungen des zentralen Nervensystems
DE69110779T2 (de) Schilddrüsenhormone zur kardialen behandlung.
DE3785401T2 (de) Verwendung von Phenylethanolaminen zur Herstellung von Arzneimitteln, wirksam für gastrointestinale Beschwerden.
WO1996037198A1 (de) Inhalative verwendung von antidepressiva zur behandlung von asthma
DE69834638T2 (de) Zusammensetzung zur Behandlung von Augenhypertension oder Glaukom
DE60207442T2 (de) VERWENDUNG EINER KOMBINATIONSZUSAMMENSETZUNG BESTEHEND AUS PROPIONYL L-CARNITIN UND WEITEREn WIRKSTOFFEn ZUR BEHANDLUNG DER EREKTILEN DYSFUNKTION
DE60123528T2 (de) Verwendung eines Mittels zur Verbesserung der Astrozytenfunktion zur Behandlung von Parkinsons Krankheit
DE3234537C2 (de) Verwendung von 3-(2,2,2-Trimethylhydrazinium)propionatdihydrat zur Behandlung kardiovaskulärer Erkrankungen
DE10163667B4 (de) Verwendung von Desoxypeganin zur Behandlung der klinischen Depression
DE69917809T2 (de) Verwendung von Bernsteinsäure oder deren Salze zur Behandlung von Insulinresistenz
EP0132595B1 (de) Tokolytisches Mittel
DE2611976A1 (de) Pharmazeutisches praeparat zur besserung und wiederherstellung bei verminderten bewusstseinszustaenden
DE4100361C1 (OSRAM)
DE2128730A1 (de) Mittel zur Kompensierung eines Dopaminmangels im Gehirn
DE60127571T2 (de) Tiagabine zur behandlung von diabetischer neuropathie
DE2754148A1 (de) Substituierte aminoaethanole, verfahren zu ihrer herstellung und ihre verwendung als arzneistoffe
DE3744542B4 (de) Pharmazeutische Verwendung von L-δ-Hydroxylysin

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
D2 Grant after examination
8328 Change in the person/name/address of the agent

Free format text: VOSSIUS, V., DIPL.-CHEM. DR.RER.NAT. TAUCHNER, P., DIPL.-CHEM. DR.RER.NAT. HEUNEMANN, D., DIPL.-PHYS. DR.RER.NAT. RAUH, P., DIPL.-CHEM. DR.RER.NAT., PAT.-ANWAELTE, 8000 MUENCHEN

8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Free format text: TAUCHNER, P., DIPL.-CHEM. DR.RER.NAT. HEUNEMANN, D., DIPL.-PHYS. DR.RER.NAT. RAUH, P., DIPL.-CHEM. DR.RER.NAT., PAT.-ANWAELTE, 8000 MUENCHEN